fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Linagliptin

All products: general benefit

Trajenta · DIN 02370921 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Trajenta · DIN 02370921 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-09-28 Health Canada: Marketed since 2011-09-13 · brand TRAJENTA · ATC A10BH05 LINAGLIPTIN · form Tablet · route Oral · ingredients LINAGLIPTIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trajenta: Formulary list price $2.81 per unit (the source does not state the unit; exact figure $2.8120). What the ministry pays, not the patient.

Ministry pays: $2.8120 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370921)

Source record
DIN 02370921: Trajenta Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002041; group id 748; item number 1831; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8120; ministry $2.8120 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370921 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85612 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370921
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B, A10BH): coverage varies; not interchangeable

  • Saxagliptin (Onglyza): general benefit
  • Sitagliptin (Januvia): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

11 more in the class list below

Linagliptin & metformin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Jentadueto · DIN 02403250 · 2.5 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Jentadueto · DIN 02403250 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2014-03-27 Health Canada: Marketed since 2013-04-17 · brand JENTADUETO · ATC A10BD11 METFORMIN AND LINAGLIPTIN, A10BD11 METFORMIN AND LINAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, LINAGLIPTIN 2.5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jentadueto: Formulary list price $1.47 per unit (the source does not state the unit; exact figure $1.4744). What the ministry pays, not the patient.

Ministry pays: $1.4744 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02403250)

Source record
DIN 02403250: Jentadueto Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002048; group id 749; item number 1833; lccId None; manufacturer id BOE Source form: Tab; strength: 2.5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4744; ministry $1.4744 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02403250 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88807 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Shortage status: resolved shortage (ended February 26, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403250
Shortage record checked October 6, 2026

Jentadueto · DIN 02403269 · 2.5 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Jentadueto · DIN 02403269 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2014-03-27 Health Canada: Marketed since 2013-04-17 · brand JENTADUETO · ATC A10BD11 METFORMIN AND LINAGLIPTIN, A10BD11 METFORMIN AND LINAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, LINAGLIPTIN 2.5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jentadueto: Formulary list price $1.47 per unit (the source does not state the unit; exact figure $1.4744). What the ministry pays, not the patient.

Ministry pays: $1.4744 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02403269)

Source record
DIN 02403269: Jentadueto Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002049; group id 749; item number 1834; lccId None; manufacturer id BOE Source form: Tab; strength: 2.5mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4744; ministry $1.4744 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02403269 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88808 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Shortage status: resolved shortage (ended March 11, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403269
Shortage record checked October 6, 2026

Jentadueto · DIN 02403277 · 2.5 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Jentadueto · DIN 02403277 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2014-03-27 Health Canada: Marketed since 2013-04-17 · brand JENTADUETO · ATC A10BD11 METFORMIN AND LINAGLIPTIN, A10BD11 METFORMIN AND LINAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, LINAGLIPTIN 2.5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jentadueto: Formulary list price $1.47 per unit (the source does not state the unit; exact figure $1.4744). What the ministry pays, not the patient.

Ministry pays: $1.4744 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02403277)

Source record
DIN 02403277: Jentadueto Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002050; group id 749; item number 1832; lccId None; manufacturer id BOE Source form: Tab; strength: 2.5mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4744; ministry $1.4744 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02403277 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88809 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Shortage status: resolved shortage (ended December 14, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403277
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B, A10BH): coverage varies; not interchangeable

  • Saxagliptin (Onglyza): general benefit
  • Sitagliptin (Januvia): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

11 more in the class list below

Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SITAGLIPTIN

· 48 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN & METFORMIN

· 41 products · General benefit · strengths: 50mg & 1000mg, 50mg & 500mg, 100mg & 1000mg, 50mg & 850mg · ER Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02 and 5 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Monotherapy: TRAJENTA (linagliptin tablets) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance. Add-on combination: TRAJENTA (linagliptin tablets) is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with:  metformin  sulfonylurea (with or without metformin)  metformin and empagliflozin  basal insulin (with or without metformin) when the therapy alone listed above, along with diet and exercise, does not provide adequate glycemic control (see CLINICAL TRIALS). Geriatrics (≥65 years of age): No dosage adjustment is required based on age, however, greater sensitivity in some older individuals cannot be ruled out (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY). Pediatrics (<18 years of age): Safety and effectiveness of TRAJENTA in pediatric patients have not been established. Therefore, TRAJENTA should not be used in this patient population. https://pdf.hres.ca/dpd_pm/00060225.PDF PM date: February 25, 2021 Source product: TRAJENTA; DIN 02370921; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE JENTADUETO (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus who are:  inadequately controlled on metformin, or  already controlled with the free combination of linagliptin and metformin. JENTADUETO (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus:  in combination with a sulfonylurea, when dual therapy with metformin and a sulfonylurea do not provide adequate glycemic control, or  in combination with basal insulin, when dual therapy with metformin and basal insulin do not provide adequate glycemic control. See CLINICAL TRIALS section. Geriatrics (≥65 years of age): JENTADUETO should be used with caution in geriatric patients. As metformin is excreted via the kidney and aging can be associated with reduced renal function, care should be taken in dose selection in patients with advanced age. More careful and frequent monitoring of renal function is necessary to … https://pdf.hres.ca/dpd_pm/00060402.PDF PM date: March 5, 2021 Source product: JENTADUETO; DIN 02403250; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.